Pharmaceuticals
We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.
We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.
Explore our sectors
Meet our lawyers
News and insights
Blog Post: 01 February 2023
The Clinical Trial Regulation (EU) No 536/2014 (CTR) became fully applicable yesterday (31 January), following the end of the transition period. Therefore, the use of the Clinical Trial Information…
Blog Post: 04 January 2023
Why AI drug discovery deals are different from traditional pharma collaborations
Pharma companies have been working with artificial intelligence (AI) for a decade or more. As the cost and time of bringing a new drug to market continues to rise, pharma companies are increasingly…
Blog Post: 21 December 2022
New date for the proposal of a revised EU pharmaceutical legislation
On 25 November 2020, the European Commission announced in its Communication for a Pharmaceutical Strategy for Europe a thorough review of the EU pharmaceutical legislation, which was originally…
Blog Post: 16 December 2022
On 10 October 2022, the European Commission (EC) sent a Statement of Objections to Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe BV (Teva). The EC has provisionally found that…
Download our sector brochure
